About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, August 18th, 2015

The QualityStocks
Daily Stock List


Cortex Pharmaceuticals, Inc. (CORX)

TopPennyStockMovers, Wallstreetlivechat, TheMicrocapNews, and UltimatePennyStock reported previously on Cortex Pharmaceuticals, Inc. (CORX), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Cortex Pharmaceuticals, Inc. is a biopharmaceutical company presently involved in the discovery and development of drugs for the treatment of respiratory disorders. The Company has multiple drug development programs targeted towards the treatment of brain-related breathing disorders, including obstructive or central sleep apnea and drug-induced respiratory depression. Founded in 1987, and listed on the OTC Markets’ OTCQB, Cortex Pharmaceuticals is based in Glen Rock, New Jersey.

Drug candidates are currently derived from two platforms. One is a class of compounds called ampakines, which act as positive allosteric modulators of AMPA glutamate receptors. Several ampakines in oral and injectable form are undergoing development by Cortex Pharmaceuticals for the treatment of drug induced respiratory depression caused by opiates and anesthetics.

In preclinical and clinical studies, such drugs have shown preliminary efficacy in central sleep apnea and restored normal respiration without altering the analgesic effects of opiates or the anesthetic effects of drugs such as propofol. The Company’s compounds belong to a new generation of ampakines that do not display the undesirable side effects displayed by earlier compounds.

The other platform is the class of compounds called cannabinoids, particularly, dronabinol. In a double-blind, placebo-controlled, dose-ascending Phase 2A clinical study conducted by Cortex, dronabinol substantially improved measures of sleep apnea in a group of patients with obstructive sleep apnea. A larger 120 patient, double-blind, placebo-controlled Phase 2B clinical study is now being conducted by the University of Illinois. It is being funded by the National Institutes of Health (NIH).

Cortex Pharmaceuticals owns patents and patent applications for certain families of chemical compounds, which claim the chemical structures and their use in the treatment of diverse disorders. These patents cover, among other compounds, Cortex’s lead ampakines CX1739 and CX1942 and extend through at least 2028.

Cortex Pharmaceuticals announced this past May the earlier publication of two key scientific papers co-authored by the Chairman of its Scientific Advisory Board, Dr. John Greer, Ph.D. that show the positive effects of Cortex’s ampakines CX1739 and CX717 in treating respiratory distress in a perinatal premature rat pup model and a genetic mouse model of Pompe Disease.

Recently, Cortex Pharmaceuticals announced a partnership with the Knowledge Translation Strategy Unit of the Canadian Institutes of Health Research on the use of ampakines in the alleviation of Respiratory Depression. Through collaboration with Dr. John Greer, Ph.D., Chairman of the Company's Scientific Advisory Board and Professor of Physiology and AIHS Senior Scientist with the Neuroscience and Mental Health Institute at the University of Alberta, a research grant has been awarded by the Canadian Institutes of Health Research in the approximate amount of C$145,000 to partially fund the development of CX1942 and related compounds for the alleviation of different forms of respiratory depression. As the Principal Investigator, Dr. Greer will be leading the research and development effort.

Cortex Pharmaceuticals, Inc. (CORX), closed Tuesday's trading session at $0.0216, down 4.00%, on 556,355 volume with 15 trades. The average volume for the last 60 days is 271,969 and the stock's 52-week low/high is $0.015/$0.09.

Vantage mHealthcare, Inc. (VNTH)

TheMicrocapNews and BUYINS.NET reported previously on Vantage mHealthcare, Inc. (VNTH), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Vantage mHealthcare, Inc. is a mobile health technology company. It is developing personalized and point-of-care screening using applications (apps) based on chemical sensing residing within a Bluetooth device that works with any smartphone, tablet, or laptop. Vantage Health is the first non-invasive, inexpensive, mobile, early cancer screening and monitoring platform. The Company has offices in Mountain View, California and New York, New York. Vantage mHealthcare’s shares trade on the OTC Markets Group’s OTCQB.

The Company has been developing a low cost point-of-care screening device. This device will detect and analyze common components from human breath and provide an early indication of chronic diseases including heart failure and various forms of cancer, and also contagious diseases such as strep throat. The device is now in a clinical environment. The final development stage for the healthcare sensor will be formal clinical trials and eventually to obtain Food and Drug Administration (FDA) approval.

Vantage mHealthcare’s first product is the Vantage Health Sensor, which is in development. It is the union of nano-electronics, bio-informatics, and wireless technology to create the next generation mobile health application. The expectation is that the first mobile app will be for lung cancer screening with additional mobile healthcare apps in the planning stages.

The Company’s mission is to commercialize mobile breath sensor technologies, which permit Health Care providers (HCPs) to better manage the health care range - from managing illness to wellness.

Last week, Vantage mHealthcare announced that its corporate name will officially change to Nano Mobile Healthcare, Inc. This is to align the strategic direction of the Company within the growing and innovative mobile healthcare technology sector. The name change is also to avoid confusion with various other businesses that use the legacy Vantage name.

Today, Vantage mHealthcare announced that Nanobeak LLC, its parent company, has engaged China Merchants Bank New York for a private placement of $20 million in equity for Vantage mHealthcare exclusively for China. Upon closing, the $20 million equity round will be used to fund expanded laboratory facilities in Mountain View, California, recruit additional scientific staff, fund clinical trials and subsequent regulatory approval.

The prospective equity partner from China will also help Vantage mHealthcare to develop strategic partnerships in China for distribution and sales of the Nanobeak technology once development is finished and regulatory approvals have been met.

Vantage mHealthcare, Inc. (VNTH), closed Tuesday's trading session at $0.0109, up 98.18%, on 22,382,855 volume with 428 trades. The average volume for the last 60 days is 609,671 and the stock's 52-week low/high is $0.0046/$0.209.

OXIS International, Inc. (OXIS)

TopPennyStockMovers, Gryphon Digest, and PennyStocks24 reported on OXIS International, Inc. (OXIS), and today we report on the Company, here at the QualityStocks Daily Newsletter.

OXIS International, Inc. is a biotechnology company concentrating on cannabinoid therapy development and commercialization. The Company develops and commercializes innovative drugs of therapeutic molecules including cannabinoids that are focusing on numerous cancer indications. OXIS International addresses the clinical shortcomings of existing commercial products in related fields. Its wholly-owned subsidiary is Oxis Biotech, Inc. OXIS International has its corporate headquarters in Tampa, Florida.

The Company has developed relationships with some of the world's top cannabinoid researchers and institutions to advance its technologies. Its emphasis is to produce a platform of synthesized cannabinoid agents that target the treatment of cancer cells in multiple areas. It will do so using the robust compounds found in cannabinoid-producing plants.

OXIS’ wholly-owned subsidiary, Oxis Biotech, has executed definitive agreements licensing certain assets for the treatment of Multiple Myeloma. Oxis Biotech also initiated a consulting agreement with University of Pittsburgh's Professor, Dr. Xiang-Qun (Sean) Xie. The license agreement provides Oxis Biotech an exclusive worldwide license to develop and commercialize therapies for the treatment of Multiple Myeloma. Dr. Xie joined Oxis Biotech as a consultant and member of the Science Advisory Board to further develop the assets licensed to Oxis Biotech.

OXIS International has its new worldwide exclusive Patent Licensing of "P62 Chemical Agents and Multiple Myeloma Therapeutics", with Dr. Xiang-Qun (Sean) Xie. Dr. Xie, MD, PhD, EMBA is one of the world's leading cannabinoid research scientists. With the inclusion of its P62 Multiple Myeloma Therapeutics platform, OXIX is positioned to be a significant player in the large and expanding market for Myeloma Therapeutic drug therapies.

OXIS International’s focus for this year is to continue to make major progress with Oxis Biotech, Inc. through adding additional high value patents and assets to its portfolio over the very near future. At the beginning of April, subsidiary Oxis Biotech discussed during its March 31, 2015 conference call with shareholders, analysts, and other interested parties certain aspects of its immunotherapeutic development strategy. Mr. Anthony J. Cataldo, Chairman and CEO, stated that Oxis Biotech is focusing on developing immunotherapies for the treatment of triple-negative breast cancer, and multiple myeloma and associated osteolytic lesions, which are significant unmet medical needs.

Last week, Oxis Biotech, the wholly-owned subsidiary of Oxis International, announced that Dr. James J. Mule, member of the Company's Scientific Advisory Board and Associate Center Director for Translational Science at the Moffitt Cancer Center, was named a Master of Immunology by the American Association for Cancer Research (AACR) publication. The distinction recognizes Dr. Mule's contributions to cancer research. In particular, it recognizes his work to better understand how anti-tumor immune responses develop and are regulated by the body.

OXIS International, Inc. (OXIS), closed Tuesday's trading session at $0.0169, down 5.59%, on 1,528,575 volume with 53 trades. The average volume for the last 60 days is 1,554,085 and the stock's 52-week low/high is $0.01/$0.07.

SmartMetric, Inc. (SMME)

SmallCapFinancialWire, Wall Street Resources, and Greenbackers reported on SmartMetric, Inc. (SMME), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

SmartMetric, Inc. is the developer of fingerprint authenticated and activated payments cards for use by credit and debit card issuers around the world. Headquartered in Las Vegas, Nevada, the Company is a technology engineering, research and development enterprise. It has developed miniature electronic systems and software for use in the field of Biometric identification and validation for the payments industry and also the Corporate and Government sectors. SmartMetric’s shares trade on the OTC Markets Group’s OTCQB.

The Company has research and development centers in Argentina; Palo Alto, California; and Tel-Aviv, Israel. SmartMetric does its hardware and software engineering internally.

The Company has embedded inside a credit card sized identity card a fully functional biometric fingerprint reader. Joining the reader with miniaturized radio frequency technology inside the card provides for a first-rate portable biometric identity and access control solution. SmartMetric’s innovative miniature fingerprint scanner, which fits inside EMV chip credit cards, will provide an advanced biometric defense to the worldwide payments industry.

Concerning Biometrics, and more specifically, Identity Verification, SmartMetric, using advanced miniaturization of biometric fingerprint recognition and verification technology, can deliver portable in a card biometrics. Regarding Biometric Payment Security, the Company brings the strength of biometrics to the domain of payments. One hundred percent identity verification with secure transaction permits the user to safely purchase online or offline. The card is useable at ATM machines. The card has the added security of only being able to be used after one has activated it by using their fingerprint.

SmartMetric is developing a biometric activated security code display to combat online card fraud and identity theft. The Company is developing a credit card that has the cards security code or what is called a CVV number activated following the cards users fingerprint match. The SmartMetric biometric fingerprint authentication system works with EMV chip cards with the EMV chip turned on only after a successful fingerprint scan and match with the card user. It has created a miniature fingerprint reader, which resides inside the credit and debit card so no other scanning device outside of the card is required to perform a biometric scan.

SmartMetric, Inc. (SMME), closed Tuesday's trading session at $0.115, up 16.86%, on 216,618 volume with 17 trades. The average volume for the last 60 days is 61,074 and the stock's 52-week low/high is $0.02/$0.175.

Énergie Holdings, Inc. (ELED)

Pumps and Dumps, VIP STOCK ALERTS, Stockhunter.us, Liquid Pennies, Stock Brain, and HEROSTOCKS reported previously on Énergie Holdings, Inc. (ELED), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Énergie Holdings, Inc.’s focus is on acquiring and growing companies that provide specialized light-emitting diode (LED) lighting solutions to the architecture and interior design markets. Its first wholly-owned subsidiary, Énergie LLC, is now targeting the multi-billion dollar architectural, specification-grade lighting fixture segment of the North American lighting fixture market with pioneering, differentiated LED lighting products. OTCQB-listed Énergie Holdings is based in Wheat Ridge, Colorado. The Company’s subsidiary, Énergie LLC, has facilities in Zeeland, Michigan.

Énergie Holdings has a large installed base of customers in all 50 States and Canada. Énergie' LLC is based upon partnerships with different European suppliers of advanced highly efficient LED lighting technology. Énergie maintains exclusive, contractual relationships with five leading European and one Taiwanese manufacturer. No other company can sell the products the Company represents in North America.

Énergie Holdings is continuing to identify and acquire other companies that have proven expertise in LED technology. Targets include lighting fixture manufacturers that complement the Énergie LLC product offering; LED component manufacturers who own solid intellectual property (IP), and globally recognized consulting firms with experts in the current and future direction of LED technology.

Énergie Holdings has access to all patents, copyrights, and trademarks of its partners and owns the UL/CUL listings for each product it sells.  As these partners are continually developing new products, Énergie has the first right to launch these products in the North American market.

The strategy of the Énergie LLC subsidiary is to enter into exclusive sales agreements with European suppliers that have distinctive lighting products. In addition, its strategy is to bridge the divide between North American architects' and designers' desired access to unique European products and European manufacturers' desire to find a cost effective way to enter the North American markets for their products.

Énergie Holdings, through Energie LLC, received exclusive rights for rapid expansion of distribution in North America from Regent Beleuchtungskörper AG. Energie and Regent have been working together for more than ten years. Regent is a pioneering Swiss developer of LED energy efficient lighting systems. Over the past several years, Regent has developed a number of LED product families targeted at meeting North American LED lighting demands. Énergie’s plan is to launch several of those product families in 2015.

This past March, Energie Holdings announced that its wholly-owned subsidiary, Energie Lighting, received UL (Underwriters Laboratories) Listings for its DOUALA, DOUALA WHITE, and RING OF FIRE product families of LED lighting fixtures. These are the first fixtures being brought to the North American market by Energie Lighting's newest partner, RZB Gmbh of Bamberg, Germany. Energie Lighting maintains exclusive marketing rights to the North American market for the products it chooses from the RZB collection.

Énergie Holdings, Inc. (ELED), closed Tuesday's trading session at $0.0032, even for the day, on 5,046,243 volume with 48 trades. The average volume for the last 60 days is 1,050,998 and the stock's 52-week low/high is $0.0028/$0.04.


The QualityStocks
Company Corner


View Systems, Inc. (VSYM)

The QualityStocks Daily Newsletter would like to spotlight View Systems, Inc. (VSYM). Today, View Systems, Inc. closed trading at $0.0057, up 14.00%, on 2,001,000 volume with 27 trades. The stock’s average daily volume over the past 60 days is 473,414, and its 52-week low/high is $0.0035/$0.024.

View Systems, Inc. today announces an update regarding ongoing discussions with three companies regarding acquisition or merger. We have received a Letter of Intent from another one of the candidates. The particular company is a profitable, privately owned company with multiple locations and an annual revenue of $7 million. The Board of Directors is reviewing the offer.

View Systems, Inc. (VSYM) is a leading security technology products company with “state-of-the-art” technological solutions for modern security problems. Targeting the challenging business opportunities in the opening decades of the 21st century and beyond, View Systems has solutions for law enforcement facilities such as correctional institutions as well as other government agencies, schools, courthouses, event and sports venues, the military and commercial businesses.

The senior management team is comprised of successful businessmen with decades of business and professional experience in the security industry. The approach used by View Systems utilizes the expertise of this team to provide innovative solutions to security problems with reliable “cutting edge” products in conjunction with client-oriented security consulting services.

The company’s flagship product, ViewScan, is an advanced walk-through Concealed Weapons Detection System (CWD) that greatly simplifies the process of discriminating suspicious items from harmless ones. The highly sensitive, completely passive sensor technology powering the system accurately detects the location and number of threat objects such as knives, guns and razor blades while ignoring personal artifacts like coins, keys and belt buckles. A portable version of this system has only a fifteen minute setup time using only a screwdriver and it easily fits inside a golf size case.

Experts say the security industry has been the fastest-growing sector of the global economy during the past decade. Today, it is conservatively estimated to be a $100 billion-a-year industry and growing. As the business environment continues to get more complex, especially in foreign markets, View Systems is strategically positioned to capitalize on unsurpassed opportunity. Disclaimer

View Systems, Inc. Company Blog

View Systems, Inc. News:

View Systems in Discussions With Three M&A Candidates and Reviewing Letter of Intent

View Systems, Inc. Files for Patent, Begins Manufacturing of Enhanced ViewScan Product

View Systems Continues to Install Its Proprietary Scanning Systems Nationwide

On the Move Systems, Inc. (OMVS)

The QualityStocks Daily Newsletter would like to spotlight On the Move Systems, Inc. (OMVS). Today, On the Move Systems, Inc. closed trading at $1.87, up 3.31%, on 14,742 volume with 66 trades. The stock’s average daily volume over the past 60 days is 56,951, and its 52-week low/high is $0.2501/$11.04.

On the Move Systems, Inc.: The nation’s retailers are on a mission to cut delivery times to almost zero and OMVS has a solution to help them achieve this ambitious goal with its proposed shared economy courier service. Amazon has been experimenting with various technologies to slice its delivery times in order to better compete in an ever-crowded field. The company has even considered using drones to get its packages to waiting customers with lightning-fast speed.

On the Move Systems, Inc. (OMVS) specializes in the development of cutting-edge technology to transform and synchronize freight supply chain operations for a broad range of industries. The company is exploring new online tools to reduce costs and increase convenience in the tourism and travel industry, as well as new opportunities in trucking. OMVS works with a premier group of international providers to offer its services in two key divisions: Trucking Logistics and Inter-modal Freight.

Logistics are critical to the success of any operation. OMVS's Trucking Logistics division operates as one of the most competitive, full-service transportation logistics providers in the United States. Utilizing the company's ISTx Platform, this division helps customers strategize how to get from one point to another, as well as solves some of the toughest logistics challenges on the road today. OMVS's Trucking Logistics technology provides customers increased visibility, minimal-cost route effectiveness, and delivery assurance.

OMVS's Intermodal Freight division offers seamless cargo continuation, tracking, shipping and receiving of goods anywhere in the world. The company's customer service teams and drivers communicate through the ISTx Platform allowing for flexibility, control and monitoring of each freight shipment. OMVS continues to research and explore the most effective and resourceful tools in order to effectively serve customers with unique shipping requirements in the billion dollar trucking industry.

In his more than 20 years of experience, OMVS president and CEO Robert Wilson has cultivated vast expertise as an executive and financial consultant for companies in aviation, energy, oil and gas, IT and healthcare. In addition to his work valuing and assessing small-to-middle market companies, Wilson has also served as both an officer and director of such client companies. Wilson applies his expertise in the transportation business and investment banking to spearhead OMVS's new initiative to create a new kind of online transportation platform to an international market Disclaimer

On the Move Systems, Inc. Company Blog

On the Move Systems, Inc. News:

OMVS: Shared Economy Couriers Can Help Retailers Reduce Delivery Times to Nearly Zero

OMVS: Climbing Air Freight Volumes Could Mean More Business for Shared Economy Couriers

OMVS: Survey Reveals Shared Economy Platforms Leading Uber-Style Trucking Revolution

International Stem Cell Corp. (ISCOD)

The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCOD). Today, International Stem Cell Corp. closed trading at $3.464, off by 6.12%, on 11,917 volume with 30 trades. The stock’s average daily volume over the past 60 days is 19,851, and its 52-week low/high is $1.25/$18.15.

International Stem Cell Corp. today provided a business update and announced operating results for the three and six months ended June 30, 2015. "Stable increase in revenues from our biomedical businesses, ability to generate net income as a parent company and progress in demonstrating the safety and efficacy of our stem cells for the treatment of Parkinson's disease and stroke position us as a leader in regenerative medicine field," stated Andrey Semechkin, Ph.D., CEO and Co-Chairman of ISCO.

International Stem Cell Corp. (ISCOD) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent portfolio offering clean intellectual property and freedom to operate. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

The company’s human stem cells have been shown to be as pluripotent as embryonic stem cells, however their creation does not involve the destruction of a viable human embryo, which effectively sidesteps the controversy and ethical dilemmas associated with the use of human embryonic stem cells. In contrast to induced pluripotent stem cells, ISCO’s stem cells do not involve manipulation of cells’ genome thereby avoiding potential safety and regulatory obstacles in clinical applications.

The company's scientists are currently focused on using its stem cells to treat severe unmet medical needs of the central nervous system (Parkinson’s disease), the liver and the eye, where cell therapy has been clinically proven but is limited due to the unavailability of safe human cells. Once the technology has been clinically validated there are an essentially unlimited number of potential applications. Because of their immune-matching ability a relatively small number of these stem cell lines could offer the potential of producing the first true stem cell bank as a means of serving populations of different immune types across the globe.

In addition to its therapeutic focus, ISCO also provides a growing revenue stream through two wholly owned subsidiaries. Lifeline Cell Technology specializes in producing primary human cells and growth media for biological research, and Lifeline Skin Care, the company manufactures and markets advanced anti-aging skincare products utilizing the company’s expertise in stem cell biology. Disclaimer

International Stem Cell Corp. Company Blog

International Stem Cell Corp. News:

International Stem Cell Corporation Announces Record Net Income in Second Quarter 2015

International Stem Cell Corporation Announces 1:150 Reverse Stock Split

International Stem Cell Corporation to Present at International Society for Cellular Therapy Annual Meeting

The Aristocrat Group Corp. (ASCC)

The QualityStocks Daily Newsletter would like to spotlight The Aristocrat Group Corp. (ASCC). Today, The Aristocrat Group Corp. closed trading at $2.35, off by 14.55%, on 19,728 volume with 59 trades. The stock’s average daily volume over the past 60 days is 6,426, and its 52-week low/high is $0.51/$6.00.

Aristocrat Group Corp. sponsored artist Curtis Braly performed for the largest audience of his career so far recently at the kickoff to his All About the Ride Tour at Houston’s Bayou Music Center. The event, held earlier this month at one of North America’s top-drawing live-music theaters, was co-sponsored by ASCC’s RWB Ultra-Premium Handcrafted Vodka. RWB Vodka signage was displayed prominently on the venue’s large projection screens, introducing the highly decorated American-made spirit to a huge number of country music fans.

The Aristocrat Group Corp. (ASCC) is a brand management company specializing in the discovery and promotion of unique brands with mass market appeal. The company strategizes to capitalize on unprecedented brand-building opportunities, and is working to build a portfolio of successful brands to compete alongside industry leaders like Moet Hennessy, Louis Vuitton, Diageo PLC, and Brown-Forman Corp.

Luxuria Brands, an ASCC subsidiary, is tasked with brand management and sustainability, specifically in the beverage alcohol sector, where the company will develop and market brands using strategic, cross-cultural branding initiatives that engage businesses and consumers. Vodka boasts a significantly high market share, accounting for 25 percent of all distilled spirits sold in the United States. What this means for ASCC investors is that they have a remarkable chance to capitalize on a proven commodity and business model for distribution.

To this accord, ASCC's current portfolio of premium luxury goods brands includes top-shelf distilled spirits like RWB Vodka, an ultra-premium handcrafted spirit that has already met remarkable success, including multiple awards. The market for vodka is estimated to be at almost 60 million cases per year in the United States alone, and beverages priced at a premium level are garnering top-dollar returns for businesses and investors. Strategizing to capitalize on this powerful sector, ASCC plans to debut a second lifestyle vodka brand later this year.

ASCC's experienced and visionary management team is committed to creating a solid foundation for innovative technologies and models, ranging from mobile couponing to social engagement, that drive business forward. Building on its established presence in the lucrative beverage alcohol sector, ASCC is emerging as a trusted platform where fledgling ideas turn into commercial successes. Disclaimer

The Aristocrat Group Corp. Company Blog

The Aristocrat Group Corp. News:

ASCC-Sponsored Artist Curtis Braly Performs for His Largest Crowd Yet

ASCC to Showcase Ultra-Premium RWB Vodka at Texas Convention Next Week

ASCC Ramps Up Marketing Efforts to Repeat Successful U.S. Product Launch in Canada

Dominovas Energy Corp. (DNRG)

The QualityStocks Daily Newsletter would like to spotlight Dominovas Energy Corp. (DNRG). Today, Dominovas Energy Corp. closed trading at $0.094, up 10.59%, on 4,438,992 volume with 312 trades. The stock’s average daily volume over the past 60 days is 7,839,489 and its 52-week low/high is $0.0035/$0.45.

Dominovas Energy Corp. (DNRG) is an energy solutions company dedicated to bringing clean, sensible and reliable power to areas of the world that lack this precious commodity. Recognizing the incredible growth and profit opportunities of the green and alternative energy markets, Dominovas Energy defined a sustainable deployment model to take a leading position among alternative green energy solutions providers.

At the heart of Dominovas Energy’s Fuel Cell Division is a revolutionary energy solution powered by the RUBICON™ Series Solid Oxide Fuel Cell (SOFC) Technology. Invented by inventor, scholar, professor and visionary Dr. Shamiul Islam, RUBICON™ achieves more than 50% fuel-to-electricity efficiency, providing cost effective, clean, significantly-reduced emissions with silent operations in 100kW to multi-megawatt power arrays. The proprietary system is capable of reforming and converting multiple fuel stocks, and is expected to become the “PLATINUM Standard” by which all other fuel cell technologies are measured.

In early 2014, Dominovas Energy was acquired by Western Standard Energy Corp. in a merger transaction in which Dominovas Energy was the emerging entity. Per the acquisition, Dominovas Energy obtained Western Standard’s 49.25% ownership of award-winning renewable energy company Pro Eco Energy Ltd. Pro Eco Energy provides award-winning heating and cooling systems for commercial and public buildings, delivering the newest alternative energy technologies for energy efficient HVAC systems in a timely and cost-competitive manner.

Dominovas Energy intends to build and own fuel cell utilities worldwide, joining the ranks of some of the world’s largest and most well-known companies that are already taking advantage of the vast opportunities of fuel cell systems. The RUBICON™ is far superior to any other system on the market today, and Dominovas Energy’s ability to produce a fuel cell that accepts multiple fuel sources is invaluable to meet the demands of the mass market. Disclaimer

Dominovas Energy Corp. Blog

Dominovas Energy Corp. News:

Dominovas Energy Announces Details of Upcoming Conference Call

Dominovas Energy Corporation (DNRG) Key Management Featured in Exclusive QualityStocks Interview

Dominovas Energy Agrees to Terms for Financing


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Wall Street Resources





By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251